A new medicine to quickly reverse methamphetamine overdose
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication
['FUNDING_U01'] · CLEAR SCIENTIFIC, LLC · NIH-11178308
This project aims to develop a fast-acting medicine called CS-1103 to help people experiencing severe methamphetamine intoxication.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEAR SCIENTIFIC, LLC (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11178308 on ClinicalTrials.gov |
What this research studies
Methamphetamine intoxication is a growing health concern with no specific treatments currently available. This project focuses on developing CS-1103, a special molecule designed to quickly bind to methamphetamine in the blood. By binding to the drug, CS-1103 helps the body remove methamphetamine more rapidly through urine, effectively reversing its toxic effects. The goal is to gain FDA approval for CS-1103 to provide a much-needed antidote for acute methamphetamine intoxication. The team is currently completing early human trials and planning for the next phase.
Who could benefit from this research
Good fit: Ideal candidates would be individuals experiencing acute methamphetamine intoxication who require rapid reversal of its toxic effects.
Not a fit: Patients not experiencing acute methamphetamine intoxication would not receive direct benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this medicine could provide a life-saving treatment for individuals experiencing severe and potentially fatal methamphetamine intoxication.
How similar studies have performed: While no current therapeutics are available for meth intoxication, CS-1103 has shown promising results in animal models, and this approach represents a novel strategy for drug reversal.
Where this research is happening
CAMBRIDGE, UNITED STATES
- CLEAR SCIENTIFIC, LLC — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, XINHUA — CLEAR SCIENTIFIC, LLC
- Study coordinator: LI, XINHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.